CClinicalTrials.gg
RecruitingNCT07159282Updated Feb 11, 2026

A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers

A Phase 4 interventional study of XWRAP in Diabetic Foot, Foot Ulcer and Ulcer Foot, sponsored by Applied Biologics, LLC. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Applied Biologics, LLC · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

A multicenter, prospective, controlled clinical trial evaluating the efficacy of a single layer placental-based allograft and standard of care in the management of nonhealing diabetic foot ulcers.

Read the detailed description

This study follows a rescue design: patients in the SOC arm who fail to heal during the CAMPX Prospective Multicenter Randomized Controlled Clinical Trial will enter the Rescue trial and receive the study product.

Patients enrolled in this trial must still meet medical necessity criteria for cellular, acellular, matrix-like, products (CAMPs) recently published by the Medicare Administrative Contractor's (MAC) in their local coverage determinations (LCD).

02

Conditions studied

  • Diabetic Foot
  • Foot Ulcer
  • Ulcer Foot
  • DFU
  • Foot Ulcer Due to Type 2 Diabetes Mellitus
  • Foot Ulcer Due to Type 1 Diabetes Mellitus
  • Diabetic Foot Ulcer
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The potential subject must be at least 18 years of age or older.
  • The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.
  • If the potential subject has two or more ulcers, the target ulcer must be the same ulcer treated in the CAMPX study.
  • The potential subject must consent to using the prescribed offloading method for the duration of the study.
  • The potential subject must agree to attend the weekly study visits required by the protocol.
  • The potential subject must be willing and able to participate in the informed consent process.
  • The potential subject must have participated in the CAMPX trial in the SOC only arm and NOT achieved complete closure by the 12-week endpoint.

Exclusion criteria

Exclusion Criteria:

  • The potential subject is known to have a life expectancy of \< 6 months.
  • The potential subject's target ulcer is not secondary to diabetes.
  • The target ulcer is infected or there is cellulitis in the surrounding skin.
  • The target ulcer exposes tendon or bone.
  • There is evidence of osteomyelitis complicating the target ulcer.
  • There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
  • The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
  • The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.
  • The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
  • The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.
  • The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
  • The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
  • The potential subject has end stage renal disease requiring dialysis.
  • The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
  • The potential subject has a malnutrition indicator score \<17 as measured on the Mini Nutritional Assessment.
  • The potential subject did not participate in the CAMPX trial.
  • The potential subject participated in the CAMPX trial and was not randomized to the SOC only arm.
  • The potential subject participated in the CAMPX trial and achieved complete closure.
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    XWRAP

    Single-layer amniotic membrane + standard of care.

    Other: XWRAP

Interventions

  • OtherXWRAP

    Application of XWRAP + standard of care for up to 12 weeks.

05

What researchers measure

Primary outcomes

  1. Wound Closure

    The percentage of target ulcers achieving complete wound closure in 12 weeks.

    Time frame: 1-12 Weeks

Secondary outcomes

  1. Time to Closure

    Time to closure for the target ulcer.

    Time frame: 1-12 weeks

  2. Wound Area Reduction

    Percentage wound area reduction from TV-1 to TV-13 measured weekly with digital photographic planimetry, using imaging device, and physical examination.

    Time frame: 1-12 weeks

  3. Adverse Events

    The number of product- or procedure- related adverse events.

    Time frame: 1-12 Weeks

  4. Wound Quality of Life

    Change in quality-of-Life based on the Wound Quality of Life Questionarie \[Time Frame: TV-1, TV-4, TV-8, TV-12 / Final Visit\].

    Time frame: 1-12 weeks

  5. Forgotten Wound Score

    Change in quality-of-Life based on the Forgotten Wound Score questionaire \[Time Frame: TV-1, TV-4, TV-8, TV-12 / Final Visit\]

    Time frame: 1-12 weeks

  6. Pain, Enjoyment of Life, and General Activity Scale

    Change in pain in the target ulcer assessed using the PEG scale \[Time Frame: TV-1 to TV-13\].

    Time frame: 1-12 Weeks

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07159282
Lead sponsor
Applied Biologics, LLC
Collaborators
SerenaGroup, Inc.
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 26, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Feb 11, 2026

Study contacts

Bennett Sarver
Contact
info@serenagroups.com
1-833-865-6300
Thomas Serena, MD
Contact
info@serenagroups.com
1-833-865-6300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion